A PYMNTS Company

US: Namenda antitrust suit heats up in NY court

By  |  March 22, 2015

The New York attorney general is continuing his antitrust suit against Actavis for attempting to force patients to switch to its new Alzheimer’s medication, Namenda XR, and limiting availability of the current versio of Namenda, slated to go off patent in July.

Actavis argues that the injunction benefits its generic rivals and actually stymies future innovation.

New York won an injunction in December that blocked the firm from limiting access to Namenda, a ruling appealed by the drug maker and now before the U.S. Court of Appeals for the Second Circuit. A decision could come as soon as next month and may help define how far firms can go to shield brand-name profits from generic rivals.

 

Full Content: Philly.com

 

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.